Index RUT
P/E -
EPS (ttm) -1.52
Insider Own 66.63%
Shs Outstand 158.83M
Perf Week 1.09%
Market Cap 1.47B
Forward P/E -
EPS next Y -1.63
Insider Trans 0.51%
Shs Float 53.21M
Perf Month -32.63%
Income -235.93M
PEG -
EPS next Q -0.34
Inst Own 15.01%
Short Float 11.03%
Perf Quarter -39.78%
Sales 0.00M
P/S -
EPS this Y 58.57%
Inst Trans -
Short Ratio 9.92
Perf Half Y -14.27%
Book/sh 2.95
P/B 3.13
EPS next Y -8.23%
ROA -51.15%
Short Interest 5.87M
Perf Year -
Cash/sh 2.85
P/C 3.25
EPS next 5Y -
ROE -54.49%
52W Range 8.82 - 21.00
Perf YTD -45.75%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -50.10%
52W High -55.95%
Beta -
Dividend TTM -
Quick Ratio 19.05
Sales past 5Y 0.00%
Gross Margin -
52W Low 4.88%
ATR (14) 0.82
Dividend Ex-Date -
Current Ratio 19.05
EPS Y/Y TTM -76.42%
Oper. Margin 0.00%
RSI (14) 28.38
Volatility 5.74% 7.09%
Employees 124
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 24.71
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -269.65%
Payout -
Rel Volume 0.64
Prev Close 9.22
Sales Surprise -
EPS Surprise -28.81%
Sales Q/Q -
Earnings Mar 07 BMO
Avg Volume 591.95K
Price 9.25
SMA20 -17.61%
SMA50 -33.85%
SMA200 -32.42%
Trades
Volume 378,375
Change 0.33%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-12-23 Initiated
Deutsche Bank
Hold
$13
Oct-10-23 Initiated
William Blair
Outperform
$26
Oct-10-23 Initiated
Stifel
Buy
$26
Oct-10-23 Initiated
RBC Capital Mkts
Outperform
$24
Oct-10-23 Initiated
JP Morgan
Overweight
$21
Oct-10-23 Initiated
Guggenheim
Buy
$22
Oct-10-23 Initiated
BofA Securities
Buy
$18
Apr-16-24 11:28AM
Apr-15-24 04:20PM
(Investor's Business Daily) -17.48%
12:17PM
08:45AM
07:47AM
06:36AM
Loading…
06:36AM
06:30AM
Mar-13-24 07:00AM
Mar-07-24 02:52PM
07:00AM
Jan-22-24 07:00AM
Jan-10-24 08:32AM
Jan-02-24 07:00AM
Dec-17-23 12:35PM
Dec-12-23 07:00AM
07:00AM
Loading…
Nov-27-23 07:00AM
Nov-01-23 07:00AM
Oct-30-23 07:00AM
Oct-10-23 07:00AM
Sep-28-23 07:54PM
Sep-27-23 06:50PM
Sep-18-23 12:35PM
Sep-14-23 08:49PM
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burow Kristina Director Nov 14 '23 Buy 11.98 3,357 40,217 4,131,207 Nov 15 06:55 PM ARCH Venture Partners XII, LLC 10% Owner Nov 14 '23 Buy 11.98 3,357 40,217 4,131,207 Nov 15 06:54 PM ARCH Venture Partners XII, LLC 10% Owner Nov 13 '23 Buy 11.75 31,653 371,923 4,127,850 Nov 15 06:54 PM Burow Kristina Director Nov 13 '23 Buy 11.75 31,653 371,923 4,127,850 Nov 15 06:55 PM Burow Kristina Director Nov 10 '23 Buy 11.49 17,275 198,481 4,096,197 Nov 13 07:01 PM ARCH Venture Partners XII, LLC 10% Owner Nov 10 '23 Buy 11.49 17,275 198,481 4,096,197 Nov 13 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 09 '23 Buy 10.53 31,079 327,262 4,078,922 Nov 13 07:00 PM Burow Kristina Director Nov 09 '23 Buy 10.53 31,079 327,262 4,078,922 Nov 13 07:01 PM Burow Kristina Director Nov 08 '23 Buy 11.03 92,251 1,017,821 4,047,843 Nov 13 07:01 PM ARCH Venture Partners XII, LLC 10% Owner Nov 08 '23 Buy 11.03 92,251 1,017,821 4,047,843 Nov 13 07:00 PM Burow Kristina Director Nov 07 '23 Buy 11.50 30,192 347,208 3,955,592 Nov 07 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 07 '23 Buy 11.50 30,192 347,208 3,955,592 Nov 07 06:59 PM ARCH Venture Partners XII, LLC 10% Owner Nov 06 '23 Buy 11.55 43,082 497,597 3,925,400 Nov 07 06:59 PM Burow Kristina Director Nov 06 '23 Buy 11.55 43,082 497,597 3,925,400 Nov 07 07:00 PM Burow Kristina Director Nov 03 '23 Buy 11.38 22,420 255,140 3,882,318 Nov 07 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 03 '23 Buy 11.38 22,420 255,140 3,882,318 Nov 07 06:59 PM Burow Kristina Director Sep 29 '23 Buy 13.98 34,560 483,149 3,859,898 Sep 29 06:55 PM ARCH Venture Partners XII, LLC 10% Owner Sep 29 '23 Buy 13.98 34,560 483,149 3,859,898 Sep 29 06:53 PM ARCH Venture Partners XII, LLC 10% Owner Sep 28 '23 Buy 13.44 41,951 563,699 3,825,338 Sep 29 06:53 PM Burow Kristina Director Sep 28 '23 Buy 13.44 41,951 563,699 3,825,338 Sep 29 06:55 PM ARCH Venture Partners XII, LLC 10% Owner Sep 27 '23 Buy 12.31 24,504 301,644 3,783,387 Sep 27 08:18 PM Burow Kristina Director Sep 27 '23 Buy 12.31 24,504 301,644 3,783,387 Sep 27 08:19 PM Burow Kristina Director Sep 26 '23 Buy 11.73 34,000 398,820 3,758,883 Sep 27 08:19 PM ARCH Venture Partners XII, LLC 10% Owner Sep 26 '23 Buy 11.73 34,000 398,820 3,758,883 Sep 27 08:18 PM Burow Kristina Director Sep 25 '23 Buy 11.22 60,740 681,464 3,724,883 Sep 25 09:37 PM ARCH Venture Partners XII, LLC 10% Owner Sep 25 '23 Buy 11.22 60,740 681,464 3,724,883 Sep 25 09:38 PM ARCH Venture Partners XII, LLC 10% Owner Sep 22 '23 Buy 11.14 40,000 445,600 3,664,143 Sep 25 09:38 PM Burow Kristina Director Sep 22 '23 Buy 11.14 40,000 445,600 3,664,143 Sep 25 09:37 PM AMGEN INC 10% Owner Sep 19 '23 Buy 17.00 1,764,705 29,999,985 35,368,653 Sep 19 07:52 PM Burow Kristina Director Sep 19 '23 Buy 17.00 1,500,000 25,500,000 3,624,143 Sep 20 06:23 AM ARCH Venture Partners X, LLC 10% Owner Sep 19 '23 Buy 17.00 1,500,000 25,500,000 3,624,143 Sep 20 06:16 AM ARCH Venture Partners X, LLC 10% Owner Sep 19 '23 Buy 17.00 1,500,000 25,500,000 3,624,143 Sep 20 06:15 AM Gosebruch Henry O President & CEO Sep 19 '23 Buy 12.62 15,000 189,370 15,000 Sep 19 09:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite